Shanghai Rightongene Biotechnology Past Earnings Performance
Past criteria checks 0/6
Shanghai Rightongene Biotechnology's earnings have been declining at an average annual rate of -32.2%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 1.4% per year.
Key information
-32.2%
Earnings growth rate
-38.4%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 1.4% |
| Return on equity | -1.5% |
| Net Margin | -2.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Shanghai Rightongene Biotechnology Co., Ltd.'s (SHSE:688217) Share Price Boosted 32% But Its Business Prospects Need A Lift Too
Oct 18
Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Jul 23Investors Can Find Comfort In Shanghai Rightongene Biotechnology's (SHSE:688217) Earnings Quality
Apr 23Revenue & Expenses Breakdown
How Shanghai Rightongene Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 249 | -5 | 134 | 66 |
| 30 Jun 24 | 265 | 1 | 139 | 73 |
| 31 Mar 24 | 266 | 7 | 137 | 72 |
| 31 Dec 23 | 258 | 8 | 126 | 70 |
| 30 Sep 23 | 351 | 23 | 132 | 66 |
| 30 Jun 23 | 379 | 35 | 124 | 65 |
| 31 Mar 23 | 433 | 44 | 121 | 59 |
| 31 Dec 22 | 424 | 40 | 119 | 64 |
| 30 Sep 22 | 354 | 41 | 115 | 63 |
| 30 Jun 22 | 328 | 44 | 112 | 66 |
| 31 Mar 22 | 274 | 29 | 117 | 75 |
| 31 Dec 21 | 291 | 47 | 116 | 69 |
| 30 Sep 21 | 289 | 53 | 108 | 77 |
| 30 Jun 21 | 285 | 50 | 104 | 70 |
| 31 Mar 21 | 307 | 53 | 97 | 70 |
| 31 Dec 20 | 285 | 39 | 91 | 74 |
| 31 Dec 19 | 255 | 36 | 106 | 67 |
| 31 Dec 18 | 224 | 15 | 90 | 53 |
Quality Earnings: 688217 is currently unprofitable.
Growing Profit Margin: 688217 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688217 is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.
Accelerating Growth: Unable to compare 688217's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688217 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688217 has a negative Return on Equity (-1.51%), as it is currently unprofitable.